ReviewRecent patents on biotechnology2026
Pharmacological Applications of Fava d'anta: A Patent Review.
Review in Recent patents on biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
A significant portion of the population in low-income countries relies on medicinal plants for healthcare. Fava d'anta is an important species in Brazil due to its bioactive compounds like quercetin and rutin. These compounds have various pharmaceutical applications, but the sustainability of their exploitation is challenged by overharvesting, necessitating sustainable management practices and further biotechnological advancements. The study conducted a comprehensive review of fava d'anta patents and their applications in various pharmacological activities, which are crucial for the development of new medicines and formulations. Patents were searched in four specialized patent databases: The United States Patent and Trademark Office, the World Intellectual Property Organization (WIPO), Espacenet and the National Institute of Industrial Property (INPI). A total of 109 patents were identified through document collection, with 26 patents meeting the inclusion criteria. The analysis revealed a global concentration of innovation in regions like Europe and the United States. Fava d'anta has demonstrated a wide range of therapeutic properties, including antioxidant and anti-inflammatory effects, largely attributed to polyphenols. These bioactive components have shown potential in diverse applications, from nutraceuticals to cosmetics. Patent registrations highlight the significant potential of Dimorphandra species for phytoproducts, particularly due to compounds like quercetin and rutin, but further studies are needed to explore their mechanisms of action and enhance technological applications, especially in cosmetics.
Indexed as
Identifiers
40211995What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.